Abbott Laboratories is among several companies racing to develop hepatitis C pills to replace the standard yearlong injectable treatment. Photographer: Tim Boyle/Bloomberg
Abbott Laboratories is among several companies racing to develop hepatitis C pills to replace the standard yearlong injectable treatment. Photographer: Tim Boyle/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=423054408&utmp=%2Fphoto%2F2012-10-15%2Fabbott-s-hepatitis-c-drugs-clear-virus-in-99-of-patients&utmhn=10.248.67.14&utmac=UA-11413116-12&utmhid=873283922)